Domestic pharm companies failed in patent challenges to leukemia therapy ‘Tasigna’

Domestic pharmaceutical companies challenged to a substance patent of ‘Tasigna,’ a Novartis’ chronic myelogenous leukemia therapy, but failed.

According to the industry on the 8^th, Kukje Pharm and Navi Pharm applied for a nullification trial for the term extension of the Tasigna’s ‘inhibitor of Tyrosine Kinase’ patent, but the Intellectual Property Tribunal dismissed it on the 5^th.

The patent...